WallStSmart

Fortrea Holdings Inc. (FTRE)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2328% more annual revenue ($65.77B vs $2.71B). MRK leads profitability with a 13.6% profit margin vs -16.5%. FTRE appears more attractively valued with a PEG of 0.34. MRK earns a higher WallStSmart Score of 50/100 (D+).

FTRE

Hold

40

out of 100

Grade: F

Growth: 2.0Profit: 2.5Value: 5.7Quality: 2.5
Piotroski: 3/9Altman Z: -0.64

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FTRESignificantly Overvalued (-39.5%)

Margin of Safety

-39.5%

Fair Value

$8.31

Current Price

$20.40

$12.09 premium

UndervaluedFair: $8.31Overvalued
MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$130.40

$49.17 premium

UndervaluedFair: $81.23Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FTRE1 strengths · Avg: 10.0/10
PEG RatioValuation
0.3410/10

Growing faster than its price suggests

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

FTRE4 concerns · Avg: 2.8/10
Market CapQuality
$1.69B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.5%3/10

Operating margin of 0.5%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-85.0%2/10

ROE of -85.0% — below average capital efficiency

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : FTRE

The strongest argument for FTRE centers on PEG Ratio. PEG of 0.34 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : FTRE

The primary concerns for FTRE are Market Cap, Operating Margin, Piotroski F-Score. Debt-to-equity of 2.13 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

FTRE profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

FTRE carries more volatility with a beta of 2.01 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 40/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fortrea Holdings Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?